Sign up with your email address to receive news and updates.
FDA has granted Breakthrough Device Designation to C2N’s proprietary blood test for the initial screening of amyloid pathology in the brain associated withAlzheimer’s Disease
C2N is conducting the PARIS Study, a two-phase pivotal clinical trial evaluating the clinical diagnostic performance of its test in individuals at high risk for Alzheimer’s Disease
C2N Diagnostics • Center for Emerging Technologies • 20 South Sarah Street • Saint Louis, MO 63108
© 2019 C2N Diagnostics LLC. All rights reserved.
Powered by Squarespace.